Frontiers in Neuroscience · 2021 · 58 citations · 39 references
MedicineClinical SciencesInfectious DiseasesClinical CardiologyEmerging Infectious DiseasesImmunopathologyAutonomic DisordersAutonomic Nervous System DisordersAutonomic Nervous System TestingCardiovascular AssessmentCardiovascular DiseaseHeart Rate VariabilityAutonomic Cardiovascular TestingAutonomic Nervous System AssessmentAutonomic Nervous System DysfunctionBlood Pressure VariabilityCardiovascular Autonomic Reflex TestingSars-cov-2 InfectionSars-cov-2 PneumoniaSevere Acute Respiratory Syndrome
Background We are facing the outburst of coronavirus disease 2019 (COVID-19) defined as a serious, multisystem, disorder, including various neurological manifestations in its presentation. So far, autonomic dysfunction (AD) has not been reported in patients with COVID-19 infection. Aim Assessment of AD in the early phase of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). Patients and methods We analyzed 116 PCR positive COVID-19 patients. After the exclusion of 41 patients with associate diseases (CADG), partitioned to patients with diabetes mellitus, hypertension, and syncope, the remaining patients were included into a severe group (45 patients with confirmed interstitial pneumonia) and mild group (30 patients). Basic cardiovascular autonomic reflex tests (CART) were performed, followed by beat-to-beat heart rate variability (HRV) and systolic and diastolic blood pressure variability (BPV) analysis, along with baroreceptor sensitivity (BRS). Non-linear analysis of HRV was provided by Poincare Plot. Results were compared to 77 sex and age-matched controls. Results AD (sympathetic, parasympathetic, or both) in our study has been revealed in 51.5% of severe, 78.0% of mild COVID-19 patients, and the difference compared to healthy controls was significant ( p = 0.018). Orthostatic hypotension has been established in 33.0% COVID-19 patients compared to 2.6% controls ( p = 0.001). Most of the spectral parameters of HRV and BPV confirmed AD, most prominent in the severe COVID-19 group. BRS was significantly lower in all patients (severe, mild, CADG), indicating significant sudden cardiac death risk. Conclusion Cardiovascular autonomic neuropathy should be taken into account in COVID-19 patients’ assessment. It can be an explanation for a variety of registered manifestations, enabling a comprehensive diagnostic approach and further treatment.
39
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Task Force of the European Society of Cardiology the North A Electrophysiology · Circulation · 1996 · 16.9K citations